Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement

Name: Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement
Creator: Brett King
Published: 2021-06-04T08:45:41.243Z
Keywords: Alopecia Areata

King, Brett; Ko, Justin; Forman, Seth; Ohyama, Manabu; Mesinkovska, Natasha; Yu, Guanglei; McCollam, Jill; Gamalo, Margaret; Janes, Jonathan; Emily, Edson-Heredia; Holzwarth, Katrin; Dutronc, Yves

doi:10.17632/sd554hbbjb.2

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement

Published: 4 June 2021| Version 2 | DOI: 10.17632/sd554hbbjb.2

Contributors:

Brett King, Justin Ko, Seth Forman, Manabu Ohyama, Natasha Mesinkovska, Guanglei Yu, Jill McCollam, Margaret Gamalo, Jonathan Janes, Edson-Heredia Emily, Katrin Holzwarth, Yves Dutronc

Description

Supplemental material for manuscript published in the Journal for the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.05.050

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement

Description

Files

Categories

Licence